Advances in liposome research in the field of antitumor

Open Access

Issue		BIO Web Conf. Volume 61, 2023 6^th International Conference on Frontiers of Biological Sciences and Engineering (FBSE 2023)


Article Number		01013
Number of page(s)		10
DOI		https://doi.org/10.1051/bioconf/20236101013
Published online		21 June 2023

Hu Gao-Yong, Wang Shu-Hang, Zhang Yu. Development of liposomes in antitumor research. Chinese Journal of Pharmacy. Vol. 18 (2020) No.1, p. 62-78. [Google Scholar]
Han X, Ding GY, Dong Q et al. Research progress of liposome-based nanogene vectors. Applied Chemistry. Vol. 35 (2018) No.07, p.735-744. [Google Scholar]
Li Jianxiong, Geng Shuang, Hu Shujian et al. Advances in functional structure design and applications of liposome delivery systems. Advances in Chemical Engineering. p. 1-12. [Google Scholar]
Sibgha Batool, Saba Sohail, Fakhar Ud Din, Ali H. Alamri. A detailed insight of the tumor targeting using nanocarrier drug delivery system. Drug Delivery. Vol. 30 (2023) No.1, p. 2183815. [CrossRef] [PubMed] [Google Scholar]
Yang B, Song B, Shankar S, et al. Recent advances in liposome formulations for breast cancer therapeutics. Cellular and Molecular Life Sciences. Vol. 78 (2021) No. 13, p. 5225-5243. [Google Scholar]
JIANG Qian,YUE Dong,GU Zhongwei. Research progress and clinical application overview of liposome delivery system. China Advances in Materials. Vol. 36 (2017) No. 11, p. 813-826+851. [Google Scholar]
J W, Y W, J J, et al. Dual-Modality Molecular Imaging of Tumor via Quantum Dots-Liposome-Microbubble Complexes. Pharmaceutics. Vol. 14 (2022) No. 11, p. 2510. [PubMed] [Google Scholar]
Chai Yamin: Preparation, characterization and properties of selenium-doped hydroxyapatite biomaterials. (Master, Tianjin University, China 2015). [Google Scholar]
Liu L: Preparation and stability study of cinnamaldehyde liposomes. (Master, Jiangnan University, China 2017). [Google Scholar]
Tang J, Liu RFA, Dai ZF. Multifunctional liposome drug delivery system. Advances in Chemistry. Vol. 30 (2018) No. 11, p.1669-1680. [Google Scholar]
KE Xue, HUANG Zhifeng, DONG Xiaohui, XU Ying. Study on the preparation of liposomes of bloodroot bases. China Natural Medicines. (2008) No.6, p.435-438. [Google Scholar]
Gu Huafang, Xu Ge, Zhu Kewu et al. Advances in active drug delivery technology of liposomes. Chinese Journal of Pharmacy. Vol. 19 (2021) No.06, p.173-185. [Google Scholar]
Rui Sang, Bradley Stratton, Alexander Engel, et al. Liposome technologies towards colorectal cancer therapeutics. Acta Biomaterialia. Vol. 127 (2021), p. 24-40. [CrossRef] [Google Scholar]
Seyed Hossein Kiaie, Solmaz Mojarad-Jabali, Farnaz Khaleseh, et al. Axial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives. International Journal of Pharmaceutics. Vol. 581 (2020), p. 119269. [CrossRef] [Google Scholar]
C G, L Z, Z T, et al. Preparation, characterization, and anti-colon cancer activity of oridonin-loaded long-circulating liposomes. Pharmaceutical development and Technology. Vol. 26 (2021) No. 10, p. 1073-1078. [PubMed] [Google Scholar]
C C, R M, R R, et al. PEGylated Liposomes Loaded with Carbamate Inhibitor ANP0903 Trigger Apoptosis by Enhancing ER Stress in HepG2 Cancer Cells. International journal of molecular Sciences. Vol. 24 (2023) No. 5, p. 4552. [PubMed] [Google Scholar]
Zhang Q, Li S, Wu W, et al. PASylation improves pharmacokinetic of liposomes and attenuates anti-PEG IgM production: An alternative to PEGylation. Nanomedicine: Nanotechnology, Biology, and Medicine. Vol. 47 (2023), p. 102622. [CrossRef] [Google Scholar]
Liang Benjia: Research and application of integrin ανβ6-targeted immunoliposomes as tumor-specific drug carriers in colon cancer treatment. (PhD, Shandong University, China 2017). [Google Scholar]
Yang G,Zhang JX,Yin B. Inhibitory effect of EGFR antibody-modified long-circulating cationic immunoliposomal reprint miR-135a on gallbladder cancer cells. Chinese Electronic Journal of Liver Surgery. Vol. 7 (2018) No.05, p.414-419. [Google Scholar]
Huang Nian: Construction of compound immunoliposomes loaded with bee toxin and toadoxine and its mechanism of inhibiting the synergistic effect of Sorafenib resistance in hepatocellular carcinoma. (PhD, Chinese People's Liberation Army Naval Medical University, China 2019). [Google Scholar]
B K, D K, M M, et al. Targeting immunoliposomes to EGFR-positive glioblastoma. ESMO Open. Vol. 7 (2022) No. 1, p. 100365. [Google Scholar]
Y H, J H, H W, et al. PEGylated immunoliposome-loaded endoglin single-chain antibody enhances anti-tumor capacity of porcine α1,3GT gene. Biomaterials. Vol. 217 (2019), p. 119231. [CrossRef] [Google Scholar]
A R, Jm B, S G, et al. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. International journal of Nanomedicine. Vol. 13 (2018), p. 3451-3465. [Google Scholar]
Y L, X L, R P, et al. Targeted delivery of irinotecan to colon cancer cells using epidermal growth factor receptor-conjugated liposomes. Biomedical engineering Online. Vol. 21 (2022) No. 1, p. 53. [PubMed] [Google Scholar]
ZHANG Zenan,BI Xiaolin,SUI Zhongguo. Preparation of low-density lipoprotein ligand-modified adriamycin liposomes and evaluation of their antitumor effects. Journal of Shenyang Pharmaceutical University. Vol. 39 (2022) No. 10, p.1174-1182. [Google Scholar]
Liu Q, Zhang D, Yang Q. et al. Preparation and quality evaluation of folic acid-modified liposomes for co-delivery of erythromycin and hypertrigonelline[J]. West China Journal of Pharmacy,2022,37(02):138-143. [Google Scholar]
JI Ke, HAN Hua, HAN Bing, LIANG Luyuan, ZHU Manli, GUAN Yanbin. Preparation and in vitro antitumor activity of transferrin-modified curcumin liposomes. Chinese herbal medicine. Vol. 53 (2022) No. 18, p. 5649-5656. [Google Scholar]
J T, Q W, Q Y, et al. A stabilized retro-inverso peptide ligand of transferrin receptor for enhanced liposome-based hepatocellular carcinoma-targeted drug delivery. Acta Biomaterialia. Vol. 83 (2019), p. 379-389. [CrossRef] [Google Scholar]
B S, Ka S. Molecular mechanism of the uptake and toxicity of EGF-LipoAgNPs in EGFR-overexpressing cancer cells. Biomedicine & pharmacotherapy = Biomedecine & Pharmacotherapie. Vol. 150 (2022), p. 113085. [CrossRef] [Google Scholar]
QUEHUI Emily, WU Bin, LI Wei et al. Preparation and antitumor effects of peptide-modified raffinolactone nanoliposomes. West China Journal of Pharmacy. Vol. 37 (2022) No.06, p. 608-612. [Google Scholar]
Ren Huanhuan, Jia Guoping, Huang Jing et al. Dual-affinity aptamer-targeted liposome-mediated T-cell immunotherapy. Journal of Pharmacology. (2023) , p. 1-16. [Google Scholar]
R D, Z L, J W, et al. Design and Synthesis of Galactose-Biotin Lipid Materials for Liposomes to Promote the Hepatoma Cell-Targeting Effect. Journal of pharmaceutical Sciences. Vol. 108 (2019) No. 9, p. 3074-3081. [PubMed] [Google Scholar]
H M, A J, H T, et al. Aptamer-conjugated nanoliposomes containing COL1A1 siRNA sensitize CRC cells to conventional chemotherapeutic drugs. Colloids and surfaces. B, Biointerfaces. Vol. 218 (2022), p. 112714. [CrossRef] [Google Scholar]
M K, Bd P, H G, et al. PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation. Pharmaceutical Research. Vol. 35 (2018) No. 8, p. 154. [PubMed] [Google Scholar]
YUAN Jia-Ni,QIN Wei-Dong,HAN Li-Ying et al. Methodological study and quality characterization of long-cycle thermosensitive liposomes of trehalose by compound emulsification-solvent volatilization. Journal of Clinical Ultrasound Medicine. Vol.21 (2019) No.3, p. 161-165. [Google Scholar]
Li Qingpo: Near-infrared light-mediated controlled drug release of adriamycin photosensitive liposomes and tumor therapy. (PhD, Zhejiang University, China 2018). [Google Scholar]
M A, M H. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug metabolism and personalized Therapy. Vol. 34 (2019) No. 1. [Google Scholar]
Cai Xiaoxuan, Lu Yingnian, Qi Yi. Application areas and mechanisms of action of long-circulating liposomes. Chinese Tissue Engineering Research. Vol. 26 (2022) No. 16, p. 2613-2617. [Google Scholar]
Mf A, N A, J W, et al. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. The Journal of pharmacy and Pharmacology. Vol. 71 (2019) No. 8, p. 1185-1198. [CrossRef] [PubMed] [Google Scholar]
BÖTTGER R, PAULI G, CHAO P H, et al. Lipid-based nanoparticle technologies for liver targeting. Advanced Drug Delivery Reviews. (2020) No.154-155, p. 79-101. [Google Scholar]
Du Sang, Cui Shaohui, Chen Xingyan et al. Advances in target-modified liposome drug delivery systems. Advances in Biochemistry and Biophysics. (2022), p. 1-18. [Google Scholar]
Zou LH, Yang X, Li JILANG et al. The in vivo fate of functionalized liposomes: applications and challenges. Chinese Journal of Experimental Formulary. Vol. 29 (2023) No. 03, p. 244-253. [Google Scholar]
XIAO Lingyu,LI Qiaoling,NI Mengxiang,FANG Hongqing. Research progress on the expression and application of antibody Fab fragments. Biotechnology Letters. Vol.28 (2017) No.03, p. 397-404. [Google Scholar]
Qiu Xingxing,Bai Jiaojiao,Zhou Xiaoju. Research progress of immunoliposomes as a targeted drug delivery system. Chinese Journal of Pharmaceutical Industry. Vol. 51 (2020) No.3, p. 316-324. [Google Scholar]
CHEN Min, SUN Ping, SU Jie, KANG Yue, LI Xinpeng, ZHANG Bo. Research progress of novel drug delivery systems for protein peptide drugs[J]. Chinese Journal of Pharmacology,2022,57(15):1232-1240. [Google Scholar]
Gao JL, Li WP, Wu XD, Gao LY, Zhao DY, Zhang Y, Wang QT, Duan ZQ. Research progress of folic acid receptor-mediated targeted drug delivery system. Hebei Industrial Science and Technology. Vol: 37 (2020) No.2, p. 120-127. [Google Scholar]
Han Dongmei, Zhao Yifan, Li Jianglin et al. Progress of transferrin receptors in tumor research. Journal of Fujian Normal University (Natural Science Edition). Vol.34 (2018) No.3, p. 110-116. [Google Scholar]
D J, F W, Y Y, et al. Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models. Journal of pharmaceutical Sciences. Vol. 111 (2022) No. 2, p. 450-457. [Google Scholar]
B S, Ka S. Molecular mechanism of the uptake and toxicity of EGF-LipoAgNPs in EGFR-overexpressing cancer cells. Biomedicine & pharmacotherapy = Biomedecine & Pharmacotherapie. Vol. 150 (2022), p. 113085. [CrossRef] [Google Scholar]
WANG Jinzhi,WANG Zhicheng,CHEN Qiuhong. Research progress of peptide-modified liposome drug delivery systems. Foreign Medicine(Antibiotics Branch). Vol.42 (2021) No.5, p. 276-280+285. [Google Scholar]
Yang M, Gao YT, Zhang XY et al. Glycan-modified nano-delivery systems[J]. Chemistry of Life,2021,41(03):452-461. [Google Scholar]
Lv Ziyang,Ren Huanhuan,Nie Shengdan,Wang Shan. Design strategy and application progress of nucleic acid aptamer-targeted delivery of siRNA[J]. Chinese Journal of Pharmacology,2022,38(08):1141-1146. [Google Scholar]
ZHU Kun, YANG Zhonglan, ZHANG Xiaoqing et al. Current status of research on nucleic acid aptamer-mediated liposome-targeted delivery of antitumor drugs[J]. Chinese Journal of Experimental Formulary,2020,26(20):206-212. [Google Scholar]
J Y, T G, Z L, et al. Aptamer-Targeted Photodynamic Platforms for Tumor Therapy. ACS applied materials & Interfaces. Vol. 13 (2021) No. 24, p. 27749-27773. [PubMed] [Google Scholar]
JIANG Ya-Meng,ZHU Yan-Yan,ZHAO Yinan et al. Research progress of anti-tumor-targeted liposomes. Life Science. Vol. 28 (2016) No.9, p. 1016-1024. [Google Scholar]
Chen S,Zhang T Y,Yang M et al. pH-sensitive nanodrug carriers in tumor therapy[J]. Chemistry of Life,2020,40(03):358-368. [Google Scholar]
Zhao Dangmei,Ke Linnan,Huang Yuanli et al. Research and progress of pH-sensitive biomedical materials in drug delivery. China Pharmaceutical Affairs. Vol. 33 (2019) No. 10, p. 1157-1166. [Google Scholar]
HUANG Shiming, LI Shubei, DENG Hongtao et al. Construction of light-sensitive liposomes of dehydrocamptothecin and its in vitro anti-invasive effect on cervical cancer. Chinese Journal of Traditional Chinese Medicine. Vol. 47 (2022) No. 10, p. 2643-2651. [Google Scholar]
ZHANG Ying,XU Xiaqing,HE Meng et al. Study of photosensitive docetaxel liposomes and evaluation of their antitumor effects. Chinese Journal of Pharmaceutical Industry. Vol. 53 (2022) No.3, p. 335-344. [Google Scholar]
Ma Qiuyan,Lin Huaqing,Zhang Jing et al. New advances of magnetically targeted thermosensitive liposomes in antitumor targeted therapy. Chinese Journal of Pharmaceutical Industry. Vol. 50 (2019) No. 12, p. 1405-1412. [Google Scholar]
CHEN Jiao, LIN Dan, YANG Jie, CAI Xue-ting, WEI Guo-li, CAO Peng. Research progress on the potentiation and toxicity reduction effects of Chinese medicines against tumors. China Science:Life Sciences. Vol. 52 (2022) No.6, p. 920-934. [Google Scholar]
Zhang Zhan-Zhan,Zheng Yadan,Liu Yang. Nanomaterials for modulation of cancer immune response. Science Bulletin. Vol. 66 (2021) No.18, p. 2288-2302. [CrossRef] [Google Scholar]
X W, M S, W L, et al. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance. Theranostics. Vol. 11 (2021) No. 13, p. 6334-6354. [PubMed] [Google Scholar]
Jin Hongyue: Study on overcoming tumor EMT-related drug resistance based on enzyme-responsive liposome co-delivery of simvastatin and paclitaxel. (PhD, Shanghai Institute of Pharmaceutical Sciences, Chinese Academy of Sciences, China 2019). [Google Scholar]
Sj H, Yx Z, Fg W. Membrane fusion-mediated delivery of small-molecule HER2 tyrosine kinase inhibitor for effective tumor chemosensitization. Journal of controlled release : official journal of the Controlled Release Society. (2023) No. 357, p. 222-234. [Google Scholar]
M Z, R P, M M, et al. Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics. Pharmaceutics. Vol. 14 (2022) No. 8, p. 1620. [PubMed] [Google Scholar]
Swl L, C P, M C, et al. MicroRNA delivery through nanoparticles. Journal of controlled release : Official journal of the Controlled Release Society. Vol. 313 (2019), p. 80-95. [CrossRef] [Google Scholar]
Zou Manshu, Zhou Lili, Qiao Yong, Xia Xinhua. Research progress on the co-delivery nano-delivery system of antineoplastic drugs with anti-multidrug resistant small nucleic acids. Chinese Journal of Pharmacy. Vol. 53 (2018) No.19, p. 1621-1626. [Google Scholar]
A L, A M, Pd P, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer. Vol. 22 (2023) No. 1, p. 40. [PubMed] [Google Scholar]
F R, L E, M M, et al. Liposome-based diagnostic and therapeutic applications for pancreatic cancer. Acta Biomaterialia. Vol. 157 (2023), p. 1-23. [CrossRef] [Google Scholar]
Ren Huanhuan, Jia Guoping, Huang Jing et al. Amphipathic aptamer-targeted liposome-mediated T-cell immunotherapy. Journal of Pharmaceutical Sciences. P. 1-16. [Google Scholar]
Liu Huifang,Lei Dongqin,Qin Fen et al. Multi-stage controlled release lipid nanocomposites based on Ce6 and MMP-2 inhibitors for photodynamic-immunosynergic treatment of melanoma. China Laser. Vol. 50 (2023) No.3, p. 177-190. [Google Scholar]
L S, Y H, C W, et al. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer. Journal of controlled release : Official journal of the Controlled Release Society. Vol. 350 (2022), p. 922-932. [CrossRef] [PubMed] [Google Scholar]
Fan N, Yin D-F. Research progress of brain-targeted liposomes. Chinese Journal of Pharmaceutical Industry. Vol. 53 (2022) No.4, p. 439-445. [Google Scholar]
YANG X, ZOU Linghui, DING Wenya, ZHANG Zhongbin, CHEN Jinqing, LI Jilang, FENG Hongli, LI Yuyang, TANG Ling, FENG Jianfang. Research progress of trans-blood-brain barrier liposomes and nanomicellar targeted drug delivery system. Chinese Journal of Traditional Chinese Medicine. Vol. 47 (2022) No.22, p. 5965-5977. [Google Scholar]
Y Z, J L, C G, et al. Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy. Journal of controlled release : Official journal of the Controlled Release Society. Vol. 330 (2021), p. 641-657. [CrossRef] [PubMed] [Google Scholar]
S L, B D S R, C S, et al. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma. Journal of controlled release : Official journal of the Controlled Release Society. Vol. 307 (2019), p. 247-260. [CrossRef] [PubMed] [Google Scholar]
Sv M, A M, Tg C, et al. Liposome delivery to the brain with rapid short-pulses of focused ultrasound and microbubbles. Journal of controlled release : official journal of the Controlled Release Society. (2022) No.341, p. 605-615. [CrossRef] [PubMed] [Google Scholar]
Zhong Man, Hu Huihui, Miao Xingxing, He Hua, Hao Kun. In vivo analytical methods and pharmacokinetics of nano-drug formulations: a strategic analysis of progress and problems. Drug Evaluation Research. Vol.45 (2022) No.7, p. 1413-1425. [Google Scholar]
T Y, F L, G M, et al. Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors. Advanced drug delivery Reviews. Vol. 177 (2021), p. 113927. [CrossRef] [Google Scholar]
Zhang MANYU, Lou CHENXI, Cao AONeng. Advances in active targeting of drug-loaded liposomes in tumor therapy. Journal of Biomedical Engineering. Vol. 39 (2022) No.3, p. 633-638. [Google Scholar]
L B, Dn S, M R, et al. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. Journal of controlled release : official journal of the Controlled Release Society. (2018) No. 277, p. 1-13. [Google Scholar]
GUO Man-Man, WANG Yi. Research progress of new anti-tumor dosage forms of vincristine. Drug Evaluation Research. Vol. 43 (2020) No.11 p. 2328-2334. [Google Scholar]
V G, Jc H, R G. Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems. Pharmaceuticals (Basel, Switzerland). Vol. 14 (2021) No. 9, p. 835. [PubMed] [Google Scholar]
Jj S, A D, Ss S, et al. Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment. Journal of controlled release : Official journal of the Controlled Release Society. Vol. 329 (2021), p. 624-644. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.